We have conducted a survey to transplant physicians in the United States and Europe. Results indicate a high potential for warm perfusion. In light of the survey results and a deeper analysis of the newly formed collaboration with United Therapeutics, we forecast a slightly faster adaption of warm perfusion than previously accounted for. Our new fair value (base case) is SEK 160 (110) per share.